Dr. Jason M Melear
Claim this profileTexas Oncology - Austin Midtown
Studies Lymphoma
Studies Multiple Myeloma
20 reported clinical trials
35 drugs studied
About Jason M Melear
Education:
- Earned an MD from the University of Texas Medical Branch at Galveston in 2009.
- Completed residency in Internal Medicine at the University of Texas Health Science Center at San Antonio in 2012.
- Finished a fellowship in Hematology/Oncology at the University of Texas MD Anderson Cancer Center in 2015.
Experience:
- Practices as a hematologist and oncologist at Texas Oncology - Austin Midtown.
- Member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
Area of expertise
1Lymphoma
Stage I
Stage IV
Stage III
2Multiple Myeloma
Relapsed
Relapsed/Refractory
Affiliated Hospitals
Clinical Trials Jason M Melear is currently running
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting1 award Phase 34 criteria
Selinexor + DRd
for Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Recruiting1 award Phase 29 criteria
More about Jason M Melear
Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jason M Melear has experience with
- Nivolumab
- Rituximab
- Brentuximab Vedotin
- Lenalidomide
- Tazemetostat
- Doxorubicin
Breakdown of trials Jason M Melear has run
Lymphoma
Multiple Myeloma
Cancer
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason M Melear specialize in?
Jason M Melear focuses on Lymphoma and Multiple Myeloma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage IV.
Is Jason M Melear currently recruiting for clinical trials?
Yes, Jason M Melear is currently recruiting for 3 clinical trials in Austin Texas. If you're interested in participating, you should apply.
Are there any treatments that Jason M Melear has studied deeply?
Yes, Jason M Melear has studied treatments such as Nivolumab, Rituximab, Brentuximab Vedotin.
What is the best way to schedule an appointment with Jason M Melear?
Apply for one of the trials that Jason M Melear is conducting.
What is the office address of Jason M Melear?
The office of Jason M Melear is located at: Texas Oncology - Austin Midtown, Austin, Texas 78731 United States. This is the address for their practice at the Texas Oncology - Austin Midtown.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.